SCHEMBL19368239

SCHEMBL19368239

C=CC(=O)NCC(c1ccccc1)C(C)C

nearest known ligand 0.53

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
KCNA3 P22001 1/20 0.53
TAAR1 Q96RJ0 1/20 0.43
TGM2 P21980 2/20 0.42
CYP2C19 P33261 2/20 0.41
ALDH1A1 P00352 2/20 0.41
CYP3A4 P08684 1/20 0.41
CYP2C9 P11712 1/20 0.41
NPC1 O15118 2/20 0.41
RAB9A P51151 2/20 0.41
APAF1 O14727 1/20 0.41
SMN1; SMN2 Q16637 1/20 0.41
LTB4R Q15722 1/20 0.40
LTB4R2 Q9NPC1 1/20 0.40
MAPK1 P28482 1/20 0.40
KRAS P01116 1/20 0.39
PLA2G1B P04054 1/20 0.39
ATG4B Q9Y4P1 1/20 0.39
GPR139 Q6DWJ6 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17183746 0.84 NPC1 (0.54) TAAR1TGM2CYP2C19ALDH1A1CYP3A4
SCHEMBL28717475 0.82 TGM2 (0.48) TGM2CYP2C19ALDH1A1CYP3A4CYP2C9
SCHEMBL1924441 0.79 KCNA3 (0.65) KCNA3TAAR1NPC1RAB9ASMN1; SMN2
SCHEMBL17183649 0.78 MTNR1A (0.48) TGM2CYP2C19ALDH1A1CYP3A4CYP2C9
SCHEMBL19557264 0.78 KCNA3 (0.56) KCNA3TAAR1ALDH1A1NPC1RAB9A
SCHEMBL8943316 0.78 TGM2 (0.44) TGM2CYP2C19ALDH1A1CYP3A4CYP2C9
SCHEMBL24163953 0.76 KCNA3 (0.55) KCNA3TAAR1NPC1RAB9AAPAF1
SCHEMBL9836276 0.76 TGM2 (0.40) TGM2CYP2C19ALDH1A1CYP3A4CYP2C9
SCHEMBL17183720 0.75 MTNR1A (0.49) TGM2CYP2C19ALDH1A1CYP3A4CYP2C9
SCHEMBL10408489 0.74 MDM2 (0.47) TGM2CYP2C19ALDH1A1CYP3A4CYP2C9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9884048-B2 ERK inhibitors MERCK SHARP & DOHME CORP. (US) 2018-02-06 US disclosed
US-20170266167-A1 ERK INHIBITORS MERCK SHARP & DOHME CORP. (US) 2017-09-21 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170266167-A1 ERK INHIBITORS MAPK1, MAPK3, MAPK6 KCNA3 4549/4885TAAR1 2508/4885TGM2 3999/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.